

## Recombinant Human Butyrylcholinesterase/BCHE

Catalog No: C560

<b>Description</b>	Recombinant Human Butyrylcholine Esterase is produced by our Mammalian expression system and the target gene encoding Glu29-Leu602 is expressed with a 6His tag at the C-terminus.
<b>Source</b>	Human cells
<b>Alternative name</b>	Cholinesterase; Acylcholine Acylhydrolase; Butyrylcholine Esterase; Choline Esterase II; Pseudocholinesterase; BCHE; CHE1
<b>Accession No.</b>	P06276
<b>Predicted Molecular Weight</b>	66.12kDa
<b>Apparent Molecular Weight</b>	90kDa, reducing conditions.
<b>Quality Control</b>	Purity: greater than 95% as determined by reducing SDS-PAGE. Endotoxin: Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
<b>Formulation</b>	Supplied as a 0.2 μm filtered solution of 20mM TrisHCl, 150mM NaCl, pH 7.5.
<b>Shipping</b>	The product is shipped on dry ice pack. Upon receipt, store it immediately at the temperature listed below.
<b>Storage</b>	Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
<b>Background</b>	Butyrylcholine Esterase (BCHE) is a secreted protein that belongs to the type-B carboxylesterase/lipase family. BCHE is a major acetylcholine hydrolyzing enzyme in the circulation. It is detected in blood plasma and present in most cells except erythrocytes. BCHE is an esterase with broad substrate specificity. BCHE can contribute to the inactivation of the neurotransmitter acetylcholine. BCHE can degrade a large number of neurotoxic organophosphate esters. Thus, it plays important pharmacological and toxicological roles and is thought to be involved in the pathological progression. Defects in BCHE are the cause of butyrylcholinesterase deficiency (BChE deficiency) which is a metabolic disorder characterized by prolonged apnoea after the use of certain anesthetic drugs, including the muscle relaxants succinylcholine and other ester local anesthetics.

### SDS-PAGE

